---
document_datetime: 2023-09-21 21:05:00
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/scientific-discussion/docetaxel-winthrop-epar-scientific-discussion_en.pdf
document_name: docetaxel-winthrop-epar-scientific-discussion_en.pdf
version: success
processing_time: 0.7446944
conversion_datetime: 2025-12-27 19:47:52.820285
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## 1. Introduction

This application has been submitted as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended

Therefore,  consent  from  the  MAH  of  the  Taxotere  application,  which  had  been  submitted  as  a  full application under Art 8(3) of Directive 2001/83/EC as amended, has been given allowing access to Module  2  to  Module  5  of  the  initial  dossier  of  this  authorised  product  and  any  subsequent  postmarketing procedures submitted, assessed and approved.

As  a  consequence,  quality,  safety  and  efficacy  of  the  Docetaxel  Winthrop  medicinal  product  is identical to the up-to-date quality, safety and efficacy profile of Taxotere. Information on the scientific discussions  can  be  found  in  the  Taxotere  CHMP  assessment  report  and  in  the  European  Public Assessment Report (EPAR). The approved indications are: Breast cancer Docetaxel Winthrop (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Docetaxel  Winthrop  (docetaxel)  in  combination  with  doxorubicin  is  indicated  for  the  treatment  of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel Winthrop (docetaxel)  monotherapy is indicated for the treatment of patients  with  locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel  Winthrop  (docetaxel)  in  combination  with  trastuzumab  is  indicated  for  the  treatment  of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel  Winthrop  (docetaxel)  in  combination  with  capecitabine  is  indicated  for  the  treatment  of patients  with  locally  advanced  or  metastatic  breast  cancer  after  failure  of  cytotoxic  chemotherapy. Previous therapy should have included an anthracycline. Non-small cell lung cancer Docetaxel  Winthrop  (docetaxel)  is  indicated  for  the  treatment  of  patients  with  locally  advanced  or metastatic non-small cell lung cancer after failure of prior chemotherapy. Docetaxel Winthrop (docetaxel) in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition. Medicinal product no longer authorised

## Prostate cancer

Docetaxel Winthrop (docetaxel) in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

## Gastric adenocarcinoma

Docetaxel Winthrop (docetaxel) in combination with cisplatin and 5-fluorouracil is indicated for the treatment  of  patients  with  metastatic  gastric  adenocarcinoma,  including  adenocarcinoma  of  the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.

## SCIENTIFIC DISCUSSION

<div style=\"page-break-after: always\"></div>

## Head and neck cancer

Docetaxel Winthrop (docetaxel) in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck.

## 2. Quality aspects

Since this application is an informed consent of the Taxotere application, the quality data in support of the Docetaxel Winthrop application are identical to the up-to-date quality data of the Taxotere dossier which have been assessed and approved (including all post-marketing procedures).

3. Non-clinical aspects Since  this  application  is  an  informed  consent  of  the  Taxotere  application,  the  non-clinical  data  in support of the Docetaxel Winthrop application are identical to the up-to-date non-clinical data of the Taxotere dossier, which have been assessed and approved (including all post-marketing procedures). 4. Clinical aspects Since this application is an informed consent of the Taxotere application, the clinical data in support of the Docetaxel Winthrop application are identical to the up-to-date clinical data of the Taxotere dossier, which have been assessed and approved (including all post-marketing procedures). 5. Pharmacovigilance PSUR As  requested  by  the  CHMP  the  PSUR  cycle  of  Docetaxel  Winthrop  will  correspond  to  the  one attributed to the cross-referred product, Taxotere, until otherwise specified. Detailed description of the Pharmacovigilance system The CHMP considered that the Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements. Risk Management Plan The CHMP is of the opinion that no additional risk minimisation activities are required beyond those included in the product information and that routine pharmacovigilance was adequate to monitor the safety of the product. Medicinal product no longer authorised

## 6. Overall conclusions, risk/benefit assessment and recommendation

Since this application is an informed consent of the Taxotere application, the CHMP considered that the  risk-benefit  balance  of  Docetaxel  Winthrop  was  favourable  and  therefore  recommended  the granting of the marketing authorisation for the following indications:

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Breast cancer

Docetaxel Winthrop (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer.

Docetaxel  Winthrop  (docetaxel)  in  combination  with  doxorubicin  is  indicated  for  the  treatment  of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

Docetaxel Winthrop (docetaxel)  monotherapy is indicated for the treatment of patients  with  locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

<!-- image -->

Docetaxel  Winthrop  (docetaxel)  in  combination  with  trastuzumab  is  indicated  for  the  treatment  of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel  Winthrop  (docetaxel)  in  combination  with  capecitabine  is  indicated  for  the  treatment  of patients  with  locally  advanced  or  metastatic  breast  cancer  after  failure  of  cytotoxic  chemotherapy. Previous therapy should have included an anthracycline. Non-small cell lung cancer Docetaxel  Winthrop  (docetaxel)  is  indicated  for  the  treatment  of  patients  with  locally  advanced  or metastatic non-small cell lung cancer after failure of prior chemotherapy. Docetaxel Winthrop (docetaxel) in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Docetaxel Winthrop (docetaxel) in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Docetaxel Winthrop (docetaxel) in combination with cisplatin and 5-fluorouracil is indicated for the treatment  of  patients  with  metastatic  gastric  adenocarcinoma,  including  adenocarcinoma  of  the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. Head and neck cancer Docetaxel Winthrop (docetaxel) in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck. Medicinal product no longer authorised